Strategic Partnerships T2 Biosystems has established or pursued distribution and supplier agreements with Cardinal Health in the US and Canada, plus a Vizient partnership. This indicates a strong channel focus and validated interest from major healthcare distributors, presenting a sales path to integrate T2 diagnostic panels into hospital networks and IDN purchasing programs.

Product Expansion The company is actively expanding its diagnostic portfolio with the T2Lyme Panel and an expanded T2Candida Panel, including detection of Candida auris. This opens cross-sell opportunities to existing customers and allows targeting of hospitals and labs seeking broader rapid pathogen detection capabilities.

Sepsis Revenue Focus With two FDA-cleared sepsis diagnostics and exclusive US distribution arrangements, there is a clear emphasis on hospital-based sepsis testing. This suggests targeting large acute care facilities and sepsis-focused care networks with higher willingness to adopt rapid pathogen identification to reduce mortality and length of stay.

Laboratory Development Plans to launch T2Lyme Panel as a laboratory-developed test by early 2025 indicate a near-term procurement opportunity for community hospitals and reference labs that can adopt LDTs quickly while monitoring regulatory approvals, enabling faster initial sales cycles.

Scale & Financing Revenue is modest but growing, with ongoing funding and a recent small grant like a $265K Phase 2 award. This signals readiness to invest in pilot deployments and early-access programs with targeted clinics or hospital systems that can serve as reference sites for broader market adoption.